An update on the safety of treating relapsing-remitting multiple sclerosis.

An update on the safety of treating relapsing-remitting multiple sclerosis. Expert Opin Drug Saf. 2019 Aug 20;: Authors: Chisari CG, Toscano S, D'Amico E, Lo Fermo S, Zanghì A, Arena S, Zappia M, Patti F Abstract Introduction: In the last 20 years the armamentarium for multiple sclerosis (MS) treatment has been enriched from an increasingly wider variety of new drugs in order to reach a better control of the disease with a better patient compliance. Areas covered: With this great variety of therapeutic options, physicians may face new and major challenges. The huge amount of data from pilot studies and real-life settings showed that the first line therapies have a better safety profile. On the other hand, the risks associated with newer drugs, with more selective mechanism of action and targeting specific pathways of MS pathophysiology, are not yet fully established. In particular, real-life use of these advanced drugs has raised important safety issues as long-term effects and potential risks are not yet known and remain to be carefully evaluated. Expert opinion: No time like the present, the physician face new and major challenges in order to choose the best available therapy for MS. With the increasing number of drugs for treating MS and the lack of safety data, observational studies and post-marketing surveillance activities are crucial in order to improve the knowledge about the safety profile of these drugs and the therapeutic management in c...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research

Related Links:

CONCLUSIONS: Our data indicate that changes in lipoprotein profile and subclasses are preceded by insulin resistance and hyperinsulinemia in patients with newly diagnosed MS. PMID: 31517604 [PubMed - in process]
Source: Endocrine Regulations - Category: Endocrinology Tags: Endocr Regul Source Type: research
AbstractMultiple sclerosis (MS) is a devastating inflammatory disease of the central nervous system (CNS) associated with loss of myelin sheaths. The role of Schwan cells in the remyelination of MS lesions has been documented. However, the detailed steps of this process are unknown.Ninjurin 2 (NINJ2) encodes an adhesion protein with high expression in Schwann cells adjoining the distal piece of injured nerve. Based on the role of this protein in neurite outgrowth, it might participate in the process of nerve regeneration after nerve damage. In the present study, we genotyped twoNINJ2 single nucleotide polymorphisms (SNPs) ...
Source: Metabolic Brain Disease - Category: Neurology Source Type: research
AbstractThe aim of this study was to evaluate the immune-inflammatory, metabolic, and nitro-oxidative stress (IM&NO) biomarkers as predictors of disability in multiple sclerosis (MS) patients. A total of 122 patients with MS were included; their disability was evaluated using the Expanded Disability Status Scale (EDSS) and IM&NO biomarkers were evaluated in peripheral blood samples. Patients with EDSS ≥3 were older and showed higher homocysteine, uric acid, advanced oxidized protein products (AOPP) and low-density lipoprotein (LDL)-cholesterol and higher rate of metabolic syndrome (MetS), while high-density lipoprotein ...
Source: Metabolic Brain Disease - Category: Neurology Source Type: research
AbstractMultiple Sclerosis (MS) is a chronic inflammatory disease causing demyelination and neurodegeneration in the central nervous system (CNS). Although the exact etiology of MS is still unclear, both genetic and environmental elements are regarded as causative factors. Environmental factors can induce a cascade of events in immune system leading to neuronal death and nerve demyelination. This paper aims to compare the peripheral transcript levels ofErmin (ERMN) (a gene with putative role in cytoskeletal rearrangements during myelinogenesis) andListerin E3 Ubiquitin Protein Ligase 1 (LTN1) (a gene with functions in regu...
Source: Metabolic Brain Disease - Category: Neurology Source Type: research
Conclusions: This educational program did not reduce the risk of falls but it improved the ability to carry out activities of daily living and decreased participation restrictions in people with neurological conditions.
Source: Frontiers in Neurology - Category: Neurology Source Type: research
This study was aimed to determine the seroprevalence of Hp in MS patients and then investigates pro/anti-inflammatory cytokine levels in MS patients infected with HP and seronegative MS patients. Three hundred eighty-seven patients with MS were included in the study and were adjusted by gender and age to 420 healthy subjects.
Source: Journal of Neuroimmunology - Category: Allergy & Immunology Authors: Source Type: research
A first of its kind observational study compares effectiveness of initial treatment choices for children and adolescents with multiple sclerosis — and finds an advantage for newer agents.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news
Novartis's investigational multiple sclerosis drug ofatumumab cut the relapse rate in patients by more than half in trials comparing it to Sanofi's Aubagio as the Swiss drugmaker aims to refresh its portfolio of medicines in neurological diseases.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced longer-term data from the Phase III open-label extension studies of OPERA I, OPERA II and ORATORIO showed that patients who were treated with OCREVUS® (ocrelizumab) continuously for six years or more had reduced risk of disability progression in relapsing MS (RMS) and primary progressive MS (PPMS).
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news
(LONDON) — Harry Potter author J.K. Rowling has made a substantial donation for research into the treatment of multiple sclerosis at a center named after her late mother. The 15.3 million-pound ($18.8 million) donation announced Thursday will be used for new facilities at a research center based at the University of Edinburgh in Scotland. The author’s mother suffered from the disease and died at the age of 45. The new gift follows a major donation Rowling made in 2010 that started the Anne Rowling clinic at the university. Rowling said she is encouraged by advances being made and proud that the clinic is not on...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Disease onetime overnight Source Type: news
More News: Drugs & Pharmacology | Marketing | Multiple Sclerosis | Study